Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 3/2018

17.04.2018 | Multiple Myeloma (P Kapoor, Section Editor)

How We Manage Patients with Plasmacytomas

verfasst von: Despina Fotiou, Meletios A. Dimopoulos, Efstathios Kastritis

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To discuss the diagnostic approach, treatment options, and future considerations in the management of plasmacytomas, either solitary or in the context of overt multiple myeloma (MM).

Recent Findings

Advanced imaging techniques such as whole-body magnetic resonance imaging and positron emission tomography/computerized tomography are essential for the diagnostic workup of solitary plasmacytomas (SP) to rule out the presence of other disease foci. The role of flow cytometry and clonal plasma cell detection is currently under study together with other prognostic factors for the identification of patients with SP at high risk of progression to overt MM. Solitary plasmacytomas are treated effectively with local radiotherapy whereas systemic therapy is required at relapse. Clonal plasma cells that accumulate at extramedullary sites have distinct biological characteristics. Patients with MM and soft tissue involvement have poor outcomes and should be treated as ultra-high risk.

Summary

A revised definition of SP that distinguishes between true solitary clonal PC accumulations and SP with minimal bone marrow involvement should be considered to guide an appropriate therapeutic and follow-up approach. Future studies should be conducted to determine optimum treatment approaches for patients with MM and paraskeletal or extramedullary disease.
Literatur
1.
Zurück zum Zitat Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.CrossRefPubMed Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.CrossRefPubMed
2.
Zurück zum Zitat Moulopoulos LA, et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993;11(7):1311–5.CrossRefPubMed Moulopoulos LA, et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993;11(7):1311–5.CrossRefPubMed
3.
Zurück zum Zitat Dimopoulos MA, et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96(6):2037–44.PubMed Dimopoulos MA, et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96(6):2037–44.PubMed
4.
Zurück zum Zitat Kilciksiz S, et al. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:895765.CrossRef Kilciksiz S, et al. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:895765.CrossRef
5.
Zurück zum Zitat Galieni P, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. 2000;85(1):47–51.PubMed Galieni P, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. 2000;85(1):47–51.PubMed
6.
Zurück zum Zitat Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983;1(4):255–62.CrossRefPubMed Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983;1(4):255–62.CrossRefPubMed
7.
Zurück zum Zitat Thumallapally N, et al. Erratum to: Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017;17(1):443.CrossRefPubMedPubMedCentral Thumallapally N, et al. Erratum to: Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017;17(1):443.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat McLain RF, Weinstein JN. Solitary plasmacytomas of the spine: a review of 84 cases. J Spinal Disord. 1989;2(2):69–74.CrossRefPubMed McLain RF, Weinstein JN. Solitary plasmacytomas of the spine: a review of 84 cases. J Spinal Disord. 1989;2(2):69–74.CrossRefPubMed
9.
Zurück zum Zitat de Waal EG, et al. Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands. Br J Haematol. 2016;175(4):661–7.CrossRefPubMed de Waal EG, et al. Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands. Br J Haematol. 2016;175(4):661–7.CrossRefPubMed
10.
Zurück zum Zitat Susnerwala SS, et al. Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer. 1997;75(6):921–7.CrossRefPubMedPubMedCentral Susnerwala SS, et al. Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer. 1997;75(6):921–7.CrossRefPubMedPubMedCentral
11.
12.
Zurück zum Zitat Chim CS, et al. Extramedullary sites of involvement in hematologic malignancies: case 3. Hemorrhagic gastric plasmacytoma as the primary presentation in multiple myeloma. J Clin Oncol. 2002;20(1):344–7.CrossRefPubMed Chim CS, et al. Extramedullary sites of involvement in hematologic malignancies: case 3. Hemorrhagic gastric plasmacytoma as the primary presentation in multiple myeloma. J Clin Oncol. 2002;20(1):344–7.CrossRefPubMed
13.
Zurück zum Zitat Hill QA, et al. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood. 2014;124(8):1296–9.CrossRefPubMed Hill QA, et al. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood. 2014;124(8):1296–9.CrossRefPubMed
14.
Zurück zum Zitat Paiva B, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014;124(8):1300–3.CrossRefPubMed Paiva B, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014;124(8):1300–3.CrossRefPubMed
15.
Zurück zum Zitat Hill, Q.A., et al., Neoplastic plasma cells are demonstrable at bone marrow sites distant to solitary plasmacytoma of bone and predict for progression to multiple myeloma. ASH Annual Meeting Abstracts, 2006. 108(11): p. 3512-. Hill, Q.A., et al., Neoplastic plasma cells are demonstrable at bone marrow sites distant to solitary plasmacytoma of bone and predict for progression to multiple myeloma. ASH Annual Meeting Abstracts, 2006. 108(11): p. 3512-.
16.
Zurück zum Zitat Hotz MA, et al. Extramedullary solitary plasmacytoma of the head and neck. A clinicopathological study. Ann Otol Rhinol Laryngol. 1999;108(5):495–500.CrossRefPubMed Hotz MA, et al. Extramedullary solitary plasmacytoma of the head and neck. A clinicopathological study. Ann Otol Rhinol Laryngol. 1999;108(5):495–500.CrossRefPubMed
17.
Zurück zum Zitat Bartl R, et al. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87(3):342–55.CrossRefPubMed Bartl R, et al. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87(3):342–55.CrossRefPubMed
18.
Zurück zum Zitat Caers J, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11(1):10.CrossRefPubMedPubMedCentral Caers J, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11(1):10.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Wilder RB, et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002;94(5):1532–7.CrossRefPubMed Wilder RB, et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002;94(5):1532–7.CrossRefPubMed
21.
Zurück zum Zitat Liebross RH, et al. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999;52(3):245–9.CrossRefPubMed Liebross RH, et al. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999;52(3):245–9.CrossRefPubMed
22.
Zurück zum Zitat Caers J, et al. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow-up of multiple myeloma. Haematologica. 2014;99(4):629–37.CrossRefPubMedPubMedCentral Caers J, et al. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow-up of multiple myeloma. Haematologica. 2014;99(4):629–37.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Gleeson TG, et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skelet Radiol. 2009;38(3):225–36.CrossRef Gleeson TG, et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skelet Radiol. 2009;38(3):225–36.CrossRef
24.
Zurück zum Zitat Kropil P, et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol. 2008;18(1):51–8.CrossRefPubMed Kropil P, et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol. 2008;18(1):51–8.CrossRefPubMed
25.
Zurück zum Zitat Liebross RH, et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41(5):1063–7.CrossRefPubMed Liebross RH, et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41(5):1063–7.CrossRefPubMed
26.
Zurück zum Zitat Dimopoulos MA, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657–64.CrossRefPubMed Dimopoulos MA, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657–64.CrossRefPubMed
27.
Zurück zum Zitat Fouquet G, et al. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014;20(12):3254–60.CrossRefPubMed Fouquet G, et al. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014;20(12):3254–60.CrossRefPubMed
28.
Zurück zum Zitat Nanni C, et al. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008;22(4):513–7.PubMed Nanni C, et al. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008;22(4):513–7.PubMed
29.
Zurück zum Zitat Lu YY, et al. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37(9):833–7.CrossRefPubMed Lu YY, et al. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37(9):833–7.CrossRefPubMed
30.
Zurück zum Zitat Salaun PY, et al. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica. 2008;93(8):1269–71.CrossRefPubMed Salaun PY, et al. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica. 2008;93(8):1269–71.CrossRefPubMed
31.
Zurück zum Zitat Kim PJ, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2009;74(3):740–6.CrossRefPubMed Kim PJ, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2009;74(3):740–6.CrossRefPubMed
32.
Zurück zum Zitat Zamagni E, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50–5.CrossRefPubMed Zamagni E, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50–5.CrossRefPubMed
33.
Zurück zum Zitat Nanni C, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33(5):525–31.CrossRefPubMed Nanni C, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33(5):525–31.CrossRefPubMed
34.
Zurück zum Zitat Cavo M, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206–17.CrossRefPubMed Cavo M, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206–17.CrossRefPubMed
36.
Zurück zum Zitat Dispenzieri A, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–24.CrossRefPubMed Dispenzieri A, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–24.CrossRefPubMed
37.
Zurück zum Zitat Caers J, et al. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Ann Med. 2013;45(5–6):413–22.CrossRefPubMed Caers J, et al. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Ann Med. 2013;45(5–6):413–22.CrossRefPubMed
38.
Zurück zum Zitat Katodritou E, et al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. Am J Hematol. 2014;89(8):803–8.CrossRefPubMed Katodritou E, et al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. Am J Hematol. 2014;89(8):803–8.CrossRefPubMed
39.
Zurück zum Zitat Holland J, et al. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992;69(6):1513–7.CrossRefPubMed Holland J, et al. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992;69(6):1513–7.CrossRefPubMed
40.
Zurück zum Zitat Soutar R, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124(6):717–26.CrossRefPubMed Soutar R, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124(6):717–26.CrossRefPubMed
41.
Zurück zum Zitat Barosi G, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica. 2004;89(6):717–41.PubMed Barosi G, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica. 2004;89(6):717–41.PubMed
42.
Zurück zum Zitat Reed V, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117(19):4468–74.CrossRefPubMed Reed V, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117(19):4468–74.CrossRefPubMed
43.
44.
Zurück zum Zitat Frassica DA, et al. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989;16(1):43–8.CrossRefPubMed Frassica DA, et al. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989;16(1):43–8.CrossRefPubMed
45.
Zurück zum Zitat Aviles A, et al. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol. 1996;14(3):111–7.CrossRefPubMed Aviles A, et al. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol. 1996;14(3):111–7.CrossRefPubMed
46.
Zurück zum Zitat Bolek TW, Marcus RB, Mendenhall NP. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1996;36(2):329–33.CrossRefPubMed Bolek TW, Marcus RB, Mendenhall NP. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1996;36(2):329–33.CrossRefPubMed
47.
Zurück zum Zitat Jyothirmayi R, et al. Radiotherapy in the treatment of solitary plasmacytoma. Br J Radiol. 1997;70(833):511–6.CrossRefPubMed Jyothirmayi R, et al. Radiotherapy in the treatment of solitary plasmacytoma. Br J Radiol. 1997;70(833):511–6.CrossRefPubMed
48.
Zurück zum Zitat Tsang RW, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001;50(1):113–20.CrossRefPubMed Tsang RW, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001;50(1):113–20.CrossRefPubMed
49.
Zurück zum Zitat Ozsahin M, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):210–7.CrossRefPubMed Ozsahin M, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):210–7.CrossRefPubMed
50.
Zurück zum Zitat Weber, D.M., Solitary bone and extramedullary plasmacytoma. Hematology Am Soc Hematol Educ Program, 2005;373–6. Weber, D.M., Solitary bone and extramedullary plasmacytoma. Hematology Am Soc Hematol Educ Program, 2005;373–6.
51.
Zurück zum Zitat Alexander MP, Goodkin DE, Poser CM. Solitary plasmacytoma producing cranial neuropathy. Arch Neurol. 1975;32(11):777–8.CrossRefPubMed Alexander MP, Goodkin DE, Poser CM. Solitary plasmacytoma producing cranial neuropathy. Arch Neurol. 1975;32(11):777–8.CrossRefPubMed
52.
Zurück zum Zitat Alexiou C, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85(11):2305–14.CrossRefPubMed Alexiou C, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85(11):2305–14.CrossRefPubMed
53.
Zurück zum Zitat Burt M, et al. Medical tumors of the chest wall. Solitary plasmacytoma and Ewing’s sarcoma. J Thorac Cardiovasc Surg. 1993;105(1):89–96.PubMed Burt M, et al. Medical tumors of the chest wall. Solitary plasmacytoma and Ewing’s sarcoma. J Thorac Cardiovasc Surg. 1993;105(1):89–96.PubMed
54.
Zurück zum Zitat Chang MY, et al. Solitary plasmacytoma of bone. J Formos Med Assoc. 1994;93(5):397–402.PubMed Chang MY, et al. Solitary plasmacytoma of bone. J Formos Med Assoc. 1994;93(5):397–402.PubMed
55.
Zurück zum Zitat Galieni P, et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol. 1995;6(7):687–91.CrossRefPubMed Galieni P, et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol. 1995;6(7):687–91.CrossRefPubMed
56.
Zurück zum Zitat Mayr NA, et al. The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol. 1990;17(4):293–303.CrossRefPubMed Mayr NA, et al. The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol. 1990;17(4):293–303.CrossRefPubMed
57.
Zurück zum Zitat Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.CrossRefPubMed Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.CrossRefPubMed
58.
Zurück zum Zitat Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
59.
Zurück zum Zitat Delauche-Cavallier MC, et al. Solitary plasmacytoma of the spine. Long-term clinical course. Cancer. 1988;61(8):1707–14.CrossRefPubMed Delauche-Cavallier MC, et al. Solitary plasmacytoma of the spine. Long-term clinical course. Cancer. 1988;61(8):1707–14.CrossRefPubMed
60.
Zurück zum Zitat Dimopoulos MA, et al. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma. 2006;47(8):1553–6.CrossRefPubMed Dimopoulos MA, et al. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma. 2006;47(8):1553–6.CrossRefPubMed
61.
Zurück zum Zitat Harwood AR, Knowling MA, Bergsagel DE. Radiotherapy of extramedullary plasmacytoma of the head and neck. Clin Radiol. 1981;32(1):31–6.CrossRefPubMed Harwood AR, Knowling MA, Bergsagel DE. Radiotherapy of extramedullary plasmacytoma of the head and neck. Clin Radiol. 1981;32(1):31–6.CrossRefPubMed
62.
Zurück zum Zitat Pour L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360–4.CrossRefPubMedPubMedCentral Pour L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360–4.CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat Short KD, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–8.CrossRefPubMedPubMedCentral Short KD, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–8.CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Wu P, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230–5.CrossRefPubMed Wu P, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230–5.CrossRefPubMed
65.
Zurück zum Zitat Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93(2):345–51.CrossRefPubMed Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93(2):345–51.CrossRefPubMed
66.
Zurück zum Zitat Blade J, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805–12.CrossRefPubMed Blade J, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805–12.CrossRefPubMed
67.
Zurück zum Zitat Varga C, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169(6):843–50.CrossRefPubMed Varga C, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169(6):843–50.CrossRefPubMed
68.
Zurück zum Zitat Papanikolaou X, et al. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma. 2013;54(7):1459–64.CrossRefPubMed Papanikolaou X, et al. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma. 2013;54(7):1459–64.CrossRefPubMed
69.
Zurück zum Zitat Weinstock M, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851–8.CrossRefPubMedPubMedCentral Weinstock M, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851–8.CrossRefPubMedPubMedCentral
70.
Zurück zum Zitat Katodritou E, et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res. 2009;33(8):1137–40.CrossRefPubMed Katodritou E, et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res. 2009;33(8):1137–40.CrossRefPubMed
71.
Zurück zum Zitat Chang H, et al. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127(3):280–4.CrossRefPubMed Chang H, et al. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127(3):280–4.CrossRefPubMed
72.
Zurück zum Zitat Muchtar E, et al. Myeloma in scar tissue—an underreported phenomenon or an emerging entity in the novel agents’ era? A single center series. Acta Haematol. 2014;132(1):39–44.CrossRefPubMed Muchtar E, et al. Myeloma in scar tissue—an underreported phenomenon or an emerging entity in the novel agents’ era? A single center series. Acta Haematol. 2014;132(1):39–44.CrossRefPubMed
73.
Zurück zum Zitat Varettoni M, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–30.CrossRefPubMed Varettoni M, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–30.CrossRefPubMed
74.
Zurück zum Zitat Moreau P, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM Study. J Clin Oncol. 2017;35(25):2911–8.CrossRefPubMedPubMedCentral Moreau P, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM Study. J Clin Oncol. 2017;35(25):2911–8.CrossRefPubMedPubMedCentral
75.
Zurück zum Zitat Usmani SZ, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819–23.CrossRefPubMedPubMedCentral Usmani SZ, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819–23.CrossRefPubMedPubMedCentral
76.
Zurück zum Zitat Zamagni E, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.CrossRefPubMed Zamagni E, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.CrossRefPubMed
77.
Zurück zum Zitat Jurczyszyn A, et al. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016;57(9):2071–6.CrossRefPubMed Jurczyszyn A, et al. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016;57(9):2071–6.CrossRefPubMed
78.
Zurück zum Zitat Gozzetti A, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2012;118(6):1574–84.CrossRefPubMed Gozzetti A, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2012;118(6):1574–84.CrossRefPubMed
79.
Zurück zum Zitat Fassas AB, et al. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004;45(2):291–300.CrossRefPubMed Fassas AB, et al. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004;45(2):291–300.CrossRefPubMed
80.
Zurück zum Zitat Paludo J, et al. Myelomatous Involvement of the Central Nervous System. Clin Lymphoma Myeloma Leuk. 2016;16(11):644–54.CrossRefPubMed Paludo J, et al. Myelomatous Involvement of the Central Nervous System. Clin Lymphoma Myeloma Leuk. 2016;16(11):644–54.CrossRefPubMed
81.
Zurück zum Zitat Paubelle E, et al. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia. 2005;19(9):1702–4.CrossRefPubMed Paubelle E, et al. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia. 2005;19(9):1702–4.CrossRefPubMed
82.
Zurück zum Zitat Patriarca F, et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica. 2005;90(2):278–9.PubMed Patriarca F, et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica. 2005;90(2):278–9.PubMed
83.
Zurück zum Zitat Anagnostopoulos A, et al. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors. Leuk Lymphoma. 2004;45(11):2275–9.CrossRefPubMed Anagnostopoulos A, et al. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors. Leuk Lymphoma. 2004;45(11):2275–9.CrossRefPubMed
84.
Zurück zum Zitat Avigdor A, et al. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma. 2001;42(4):683–7.CrossRefPubMed Avigdor A, et al. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma. 2001;42(4):683–7.CrossRefPubMed
85.
Zurück zum Zitat Rosinol L, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832–6.PubMed Rosinol L, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832–6.PubMed
86.
Zurück zum Zitat Sonneveld P, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31(26):3279–87.CrossRefPubMed Sonneveld P, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31(26):3279–87.CrossRefPubMed
87.
Zurück zum Zitat Mateos MV, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259–66.CrossRefPubMed Mateos MV, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259–66.CrossRefPubMed
88.
Zurück zum Zitat Durie BG, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomized, open-label, phase 3 trial. Lancet. 2017;389(10068):519–27.CrossRefPubMed Durie BG, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomized, open-label, phase 3 trial. Lancet. 2017;389(10068):519–27.CrossRefPubMed
89.
Zurück zum Zitat San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.CrossRefPubMed San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.CrossRefPubMed
90.
91.
Zurück zum Zitat Rosinol L, et al. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. Bone Marrow Transplant. 2015;50(5):658–62.CrossRefPubMed Rosinol L, et al. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. Bone Marrow Transplant. 2015;50(5):658–62.CrossRefPubMed
92.
Zurück zum Zitat Laura R, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76(5):405–8.CrossRefPubMed Laura R, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76(5):405–8.CrossRefPubMed
93.
Zurück zum Zitat Durie BG, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73.CrossRefPubMed Durie BG, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73.CrossRefPubMed
94.
Zurück zum Zitat Mateos MV, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–47.CrossRefPubMed Mateos MV, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–47.CrossRefPubMed
Metadaten
Titel
How We Manage Patients with Plasmacytomas
verfasst von
Despina Fotiou
Meletios A. Dimopoulos
Efstathios Kastritis
Publikationsdatum
17.04.2018
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 3/2018
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-018-0452-z

Weitere Artikel der Ausgabe 3/2018

Current Hematologic Malignancy Reports 3/2018 Zur Ausgabe

Multiple Myeloma (P Kapoor, Section Editor)

Novel Approaches for the Management of AL Amyloidosis

Myeloproliferative Neoplasms (B Stein, Section Editor)

Management of Myelofibrosis-Related Cytopenias

Health Economics (N Khera, Section Editor)

Frailty in Hematologic Malignancy

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.